Aurobindo in-licenced chemotherapy induced neutropenia drug Ryzneuta gets USFDA nod
Aurobindo in-licenced chemotherapy induced neutropenia drug Ryzneuta gets USFDA nod
Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF), Ryzneuta, to treat chemotherapy-induced Neutropenia (CIN) in cancer patients. Ryzneuta is the first non-pegylated G-CSF approved by both the USFDA and China's National Medical Products Administration (NMPA). The drug was in-licensed by Aurobindo's subsidiary Acrotech Biopharma last year. Acrotech is preparing to commercialize Ryzneuta, with Aurobindo Pharma expecting more regulatory approvals in the near future.
Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF), Ryzneuta, to treat chemotherapy-induced Neutropenia (CIN) in cancer patients. Ryzneuta is the first non-pegylated G-CSF approved by both the USFDA and China's National Medical Products Administration (NMPA). The drug was in-licensed by Aurobindo's subsidiary Acrotech Biopharma last year. Acrotech is preparing to commercialize Ryzneuta, with Aurobindo Pharma expecting more regulatory approvals in the near future.
We use cookies to improve your experience on our site and to show you relevant advertising. To find out more, read our updated privacy policy and cookie policy
Through RSS Feeds 
Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF), Ryzneuta, to treat chemotherapy-induced Neutropenia (CIN) in cancer patients. Ryzneuta is the first non-pegylated G-CSF approved by both the USFDA and China's National Medical Products Administration (NMPA). The drug was in-licensed by Aurobindo's subsidiary Acrotech Biopharma last year. Acrotech is preparing to commercialize Ryzneuta, with Aurobindo Pharma expecting more regulatory approvals in the near future. 
